Dacogen
Healthcare Professionals
Get the Flash Player to see this player.
Print This Page Print This Page Send to a Friend Send to a Friend Font Size search

ABOUT DACOGEN

DACOGEN® (decitabine) for Injection is approved by the Food and Drug Administration for the treatment of myelodysplastic syndromes (MDS). DACOGEN is indicated for treatment of patients with myelodysplastic syndromes including:

  • Previously treated and untreated
  • De Novo and secondary MDS
  • French American British (FAB) subtypes
  • RA, RARS, RAEB, RAEB-t, CMML and
  • International Prognostic Scoring System (IPSS groups)
  • Intermediate-1, Intermediate-2, High-Risk

DACOGEN may help the bone marrow function more normally. This may improve MDS symptoms by increasing red blood cell count, white blood cell count, and/or platelet count. In addition to improving MDS symptoms, DACOGEN may also help impact the disease itself, correcting DNA abnormalities observed in MDS.

Learn more about DACOGEN in these sections:

DACOGEN is indicated for treatment of patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo, and secondary MDS of all FAB subtypes (RA, RARS, RAEB, RAEB-t, CMML) and Intermediate-1, Intermediate-2, and High-Risk IPSS groups.

DACOGEN may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while using DACOGEN. Men should be advised not to father a child while receiving treatment with DACOGEN, and for 2 months afterwards. The most commonly occurring adverse reactions include neutropenia, thrombocytopenia, anemia, fatigue, pyrexia, nausea, cough, petechiae, constipation, diarrhea, and hyperglycemia.

DACOGEN is available by prescription only. Please see the important product information for DACOGEN for more information. This site does not contain everything that is known about DACOGEN. If you would like to know more, talk to your healthcare professional.

Important Product Information  |  Glossary  |  Legal Notice  |  Privacy and Security  

This website is intended for U.S. residents only.
Dacogen® is a trademark of SuperGen, Inc., Dublin, CA, U.S.A. used under license.
Distributed and marketed by MGI PHARMA, INC. Bloomington, MN 55437
©2007 MGI PHARMA, INC., Bloomington, MN 55437 U.S.A. DAC135 10/07